Recipharm

A

ARTESAN

With more than 75 years of experience serving European and international markets, ARTESAN operates as a full-service contract development and manufacturing organisation within the pharmaceutical industry, guiding clients from initial product concept through to finished, market-ready goods. Since 1996 the company has been a wholly owned subsidiary of the Klosterfrau Group, combining independent operational focus with the resources of an established European healthcare holding. The manufacturing portfolio covers a broad range of solid-dose forms, including granulation, coating, dragees, film tablets, conventional tablets, lozenges and homeopathic preparations, as well as sterile single-use syringes and liquid formulations. This breadth enables ARTESAN to serve partners across multiple therapeutic categories without requiring them to engage separate manufacturing sites for different dosage forms. On the development and compliance side, the company's services extend to product development, product transfer, serialisation and aggregation, analytical services and regulatory submission support. Continuous investment in modern manufacturing and packaging technologies is a stated operating principle, alongside staff development, reflecting a dual commitment to technical capability and scientific expertise at the client-facing level. ARTESAN positions itself on high quality standards, flexible and innovative working practices, and close individual attention to each client relationship, an approach that underpins its long-standing partnerships across European and international pharmaceutical markets. Further information is available at artesan.de.

View profile

C

Cambrex

Founded in 1981, Cambrex is a leading contract development and manufacturing organisation (CDMO) serving the global pharmaceutical industry, with a specialisation in small molecule active pharmaceutical ingredients (APIs) and finished dosage forms. Its capabilities span the entire drug lifecycle, from early-stage development through commercial manufacture, making it a trusted partner for both innovator and generic pharmaceutical companies worldwide. Cambrex operates a network of manufacturing and development facilities across North America and Europe, including sites in the United States, Sweden, Italy, and the United Kingdom. This multi-site footprint gives clients geographic flexibility, regulatory coverage across major markets, and resilient supply chain options for critical medicines. The company's API development and manufacturing services encompass a broad range of chemistries, including highly potent compounds and controlled substances, supported by dedicated containment infrastructure and regulatory expertise. Cambrex also offers drug product services, covering solid oral dosage forms such as tablets and capsules, through its network of finished dose facilities. In 2019, Cambrex was acquired by private equity firm Permira and taken private, enabling further investment in capacity expansion and technology capabilities. Subsequent acquisitions, including Snapdragon Chemistry and Halo Labs, have strengthened its position in flow chemistry and drug product development respectively, reflecting a strategy of broadening its technical offering to pharmaceutical partners. Cambrex holds regulatory approvals from agencies including the US FDA and EMA, and its facilities operate under current Good Manufacturing Practice (cGMP) standards across its global network. Further information is available at cambrex.com.

View profile

C

Catalent

Catalent is one of the world's largest contract development and manufacturing organisations, supplying drug substance, drug product, and biologics capabilities to pharmaceutical and biotechnology companies across more than 40 countries. Founded in 2007 following the spin-off of Cardinal Health's pharmaceutical technologies and services division, the company built its reputation on solving formulation and delivery challenges that its clients cannot address in-house. Drug Delivery Technologies Catalent's portfolio of proprietary drug delivery platforms is a primary reason manufacturers turn to the company at early development stages. Its Softgel and Optiform technologies serve both small-molecule and biologics formulations, while the OptiMelt and Zydis orally disintegrating tablet platforms address specific bioavailability and patient-compliance challenges. These platforms are applied across therapeutic areas including oncology, rare diseases, consumer health, and central nervous system indications. Biologics & Gene Therapy Manufacturing In recent years, Catalent significantly expanded its biologics manufacturing capacity through a series of acquisitions and facility investments, most notably its purchase of the Bloomington, Indiana biologics site and the acquisition of Paragon Bioservices, which brought substantial cell and gene therapy manufacturing capability. The Harmans, Maryland gene therapy facility became one of the largest commercial-scale viral vector manufacturing sites in North America. This expansion positioned Catalent as a significant partner for advanced therapy developers requiring specialist fill-finish, cell culture, and analytical services. Catalent operates across the United States, Europe, and the Asia-Pacific region, with major sites in Somerset (New Jersey), Brussels, Swindon, and Sydney among others. The company was publicly traded on the New York Stock Exchange under the ticker CTLT before Novo Holdings announced its acquisition in 2024, subsequently transferring a number of its biologics manufacturing sites to Novo Nordisk as part of that transaction. The company serves customers ranging from the world's leading pharmaceutical groups to emerging biotech companies seeking development-stage formulation support through to commercial-scale supply. Further information is available at catalent.com.

View profile

Recipharm

About Recipharm

More in Contract Manufacturing

List Your Company

Advertise With Us